Making Assays FAIR
Researchers are using phenotypic assays at earlier and earlier stages of drug discovery. Assays for use in hit triage must be exceptional. In a previous post we’ve described the impact…
Where are we with validation of assays to replace animals for product testing? The short answer: not very far. While many innovative platforms with potential as animal alternatives have been…
Drug discovery practitioners are painfully familiar with “nuisance” compounds. These compounds may be screening hits that start out as promising actives but then are later discovered to be artifacts or…
Quietly happening beneath the radar, phenotypic platforms are becoming integrated into drug discovery processes. Why this is happening and how are phenotypic assays transforming the stages of drug discovery? Multiple…
A recent paper from NTP showcases the application of mechanism-based NAMs for prediction of cardiotoxic potential. In a previous post, Getting Back on Track with NAMs at FDA, we encouraged…
Has FDA lost it’s way with NAMs? NAMs or New Alternative Methodologies is the term used by FDA for new regulatory tools to improve predictivity and help replace, reduce and/or…
It takes courage to address common pitfalls in drug discovery and perseverance to traverse the route. In my work and as an advisor I’ve seen 100s of early-stage drug discovery…
Is coronavirus morbidity exacerbated by environmental pollution? A potential mechanism underlying thrombosis-related side effects connects multiple known risk factors. In the early days of the COVID-19 pandemic, signs that infected…
How can we incorporate human-based animal alternatives into drug discovery? Can we reduce animal testing and still improve program success? Making good decisions requires integrating information from many assays and…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…